Aspirin Oral Mucosal Formulations
Summary
USPTO published patent application US20260090985A1 for oral mucosal aspirin formulations (91-200mg micronized) with buffer and surfactant components. The application, filed by inventor James Dzandu, covers sublingual and buccal delivery formulations with pH ≤3. No regulatory obligations or compliance deadlines are imposed by this patent publication.
What changed
USPTO published patent application US20260090985A1 on April 2, 2026, disclosing pharmaceutical formulations comprising micronized aspirin (91mg to 200mg), a buffer, a surfactant, and pharmaceutically acceptable excipients for oral mucosal (sublingual and/or buccal) administration. The formulations are characterized by a pH ≤3 when dissolved in 1mL distilled water. The application also discloses methods of treating subjects by administering these formulations. Filing occurred on October 2, 2025, under application number 19348728.
This is a patent application publication, not a regulatory requirement or enforcement action. It creates no compliance obligations or deadlines. Pharmaceutical companies and drug manufacturers developing aspirin delivery systems should review the claims to assess potential freedom-to-operate implications or licensing opportunities. The patent remains pending examination and has not yet been granted.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ORAL MUCOSAL FORMULATIONS OF ASPIRIN
Application US20260090985A1 Kind: A1 Apr 02, 2026
Inventors
James Dzandu
Abstract
Disclosed herein, in part, are pharmaceutical formulations for oral mucosal (e.g., sublingual and/or buccal) administration comprising micronized aspirin, (e.g., 91 mg to 200 mg micronized aspirin), a buffer, a surfactant, and one or more pharmaceutically acceptable excipients, wherein the pH of a solution of the formulation dissolved in 1 mL distilled water is less than or equal to 3. Methods of treating a subject in need thereof comprising administering one or more disclosed pharmaceutical formulations to the subject are also provided herein.
CPC Classifications
A61K 9/006 A61K 9/1611 A61K 9/1617 A61K 9/1629 A61K 31/192 A61P 9/04
Filing Date
2025-10-02
Application No.
19348728
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Therapeutics (A61P) publishes new changes.